Systolic dysfunction in cardiac-specific ligand-inducible MerCreMer transgenic mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 1, 2011, Pages

  Hall, Michael E ^a   Smith, Grant ^a   Hall, John E ^a   Stec, David E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac hypertrophy; Cre recombinase; Tamoxifen

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRE RECOMBINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PYRUVATE DEHYDROGENASE KINASE 4; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; FEMALE; HEART FUNCTION; HEART HYPERTROPHY; HEART MITOCHONDRION; HEART WEIGHT; LOXP SITE; MALE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLE; SYSTOLIC DYSFUNCTION; TRANSGENIC MOUSE;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CYTOSKELETON; ECHOCARDIOGRAPHY; ENERGY METABOLISM; ENZYME ACTIVATION; ESTROGEN ANTAGONISTS; FEMALE; HEART FAILURE, SYSTOLIC; HYPERTROPHY, LEFT VENTRICULAR; INTEGRASES; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA, HEART; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIUM; MYOSIN HEAVY CHAINS; OXIDATIVE PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SYSTOLE; TAMOXIFEN; TRANSCRIPTION FACTORS; TUBULIN; VENTRICULAR FUNCTION, LEFT;

EID: 79959886319     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00786.2010     Document Type: Article

References (31)

1. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA, Schneider MD. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest 100: 169-179, 1997.
2. Andersson KB, Birkeland JA, Finsen AV, Louch WE, Sjaastad I, Wang Y, Chen J, Molkentin JD, Chien KR, Sejersted OM, Christensen G. Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol 47: 180-187, 2009.
3. Andersson KB, Winer LH, Mork HK, Molkentin JD, Jaisser F. Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts. Transgenic Res 19: 715-725, 2010.
4. Buerger A, Rozhitskaya O, Sherwood MC, Dorfman AL, Bisping E, Abel ED, Pu WT, Izumo S, Jay PY. Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail 12: 392-398, 2006.
5. Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, Molkentin JD, De Windt LJ. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118: 1567-1576, 2008.
6. Diggle PJ, Heagerty P, Liang KY, Zeger SL. The Analysis of Longitudinal Data. Oxford, England: University Press, 2002.
7. Doenst T, Pytel G, Schrepper A, Amorim P, Farber G, Shingu Y, Mohr FW, Schwarzer M. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86: 461-470, 2010.
8. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P. Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 93: 10887-10890, 1996.
9. Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 237: 752-757, 1997.
10. Gupta A, Gupta S, Young D, Das B, McMahon J, Sen S. Impairment of ultrastructure and cytoskeleton during progression of cardiac hypertrophy to heart failure. Lab Invest 90: 520-530, 2010.
11. Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in heart failure. Cardiovasc Res 45: 273-278, 2000.
12. Hoesl E, Stieber J, Herrmann S, Feil S, Tybl E, Hofmann F, Feil R, Ludwig A. Tamoxifen-inducible gene deletion in the cardiac conduction system. J Mol Cell Cardiol 45: 62-69, 2008.
13. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271: 12610-12616, 1996.
14. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, Iwanaga Y, Narazaki M, Matsuda T, Soga T, Kita T, Kimura T, Shioi T. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3: 420-430, 2010.
15. Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, Gabrielson KL, Takimoto E, Kass DA. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res 105: 12-15, 2009.
16. Kostin S, Hein S, Arnon E, Scholz D, Schaper J. The cytoskeleton and related proteins in the human failing heart. Heart Fail Rev 5: 271-280, 2000.
17. Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, Kanaar R, Berns A, Jonkers J. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci USA 98: 9209-9214, 2001.
18. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258, 2010.
19. Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R. Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 116: 901-909, 2007.
20. Metzger D, Clifford J, Chiba H, Chambon P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci USA 92: 6991-6995, 1995.
21. Minamino T, Gaussin V, DeMayo FJ, Schneider MD. Inducible gene targeting in postnatal myocardium by cardiac-specific expression of a hormone-activated Cre fusion protein. Circ Res 88: 587-592, 2001.
22. Naiche LA, Papaioannou VE. Cre activity causes widespread apoptosis and lethal anemia during embryonic development. Genesis 45: 768-775, 2007.
23. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, De Windt LJ, Ludosky MA, Paulin D, Daegelen D, Tuil D, Li Z. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112: 2930-2939, 2005.
24. Lang RM, Biering M, Devereux RB, Flakschampf FA, Foster E, Pellikka PA, Picard MH, Roman MA, Seward J, Shanewise JA, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Society of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463, 2005.
25. Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA 85: 5166-5170, 1988.
26. Sauer B, Henderson N. Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase. New Biol 2: 441-449, 1990.
27. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD. Temporally regulated and tissuespecific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res 89: 20-25, 2001.
28. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005.
29. Verrou C, Zhang Y, Zurn C, Schamel WW, Reth M. Comparison of the tamoxifen regulated chimeric Cre recombinases MerCreMer and CreMer. Biol Chem 380: 1435-1438, 1999.
30. Xiong D, Heyman NS, Airey J, Zhang M, Singer CA, Rawat S, Ye L, Evans R, Burkin DJ, Tian H, McCloskey DT, Valencik M, Britton FC, Duan D, Hume JR. Cardiac-specific, inducible ClC-3 gene deletion eliminates native volume-sensitive chloride channels and produces myocardial hypertrophy in adult mice. J Mol Cell Cardiol 48: 211-219, 2010.
31. Scherrer-Crosbie M, Kurtz B. Ventricular remodeling and function: insights using murine echocardiography. J Mol Cell Cardiol 48: 512-517, 2010.